Bridge Biotherapeutics Inc
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for … Read more
Bridge Biotherapeutics Inc (288330) - Net Assets
Latest net assets as of September 2025: ₩48.42 Billion KRW
Based on the latest financial reports, Bridge Biotherapeutics Inc (288330) has net assets worth ₩48.42 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩55.57 Billion) and total liabilities (₩7.15 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩48.42 Billion |
| % of Total Assets | 87.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | -55.69% |
| 10-Year Change | N/A |
| Growth Volatility | 35.16 |
Bridge Biotherapeutics Inc - Net Assets Trend (2016–2024)
This chart illustrates how Bridge Biotherapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bridge Biotherapeutics Inc (2016–2024)
The table below shows the annual net assets of Bridge Biotherapeutics Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩26.25 Billion | +35.45% |
| 2023-12-31 | ₩19.38 Billion | -62.64% |
| 2022-12-31 | ₩51.87 Billion | +20.48% |
| 2021-12-31 | ₩43.05 Billion | -27.32% |
| 2020-12-31 | ₩59.23 Billion | -21.05% |
| 2019-12-31 | ₩75.02 Billion | +263.26% |
| 2018-12-31 | ₩-45.95 Billion | -325.07% |
| 2017-12-31 | ₩-10.81 Billion | -837.69% |
| 2016-12-31 | ₩-1.15 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bridge Biotherapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14728848080000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩25.21 Billion | 96.04% |
| Other Components | ₩150.51 Billion | 573.47% |
| Total Equity | ₩26.25 Billion | 100.00% |
Bridge Biotherapeutics Inc Competitors by Market Cap
The table below lists competitors of Bridge Biotherapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Climeon AB (publ)
OTCGREY:CLMOF
|
$22.92 Million |
|
MSC Co. Ltd
KQ:009780
|
$22.92 Million |
|
Kaya Holdings Inc
OTCQB:KAYS
|
$22.93 Million |
|
YONGHE MED.GR.DL-0000025
F:L97
|
$22.94 Million |
|
Y.H. Dimri Construction & Development Ltd
TA:DIMRI
|
$22.91 Million |
|
Cimentas Izmir Cimento Fabrikasi TAS
IS:CMENT
|
$22.91 Million |
|
Green Plus Co. Ltd
KQ:186230
|
$22.91 Million |
|
IAR SA
RO:IARV
|
$22.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bridge Biotherapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,377,352,390 to 26,245,865,830, a change of 6,868,513,440 (35.4%).
- Net loss of 19,755,762,690 reduced equity.
- Share repurchases of 23,010,260,730 reduced equity.
- New share issuances of 23,020,595,720 increased equity.
- Other factors increased equity by 26,613,941,140.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-19.76 Billion | -75.27% |
| Share Repurchases | ₩23.01 Billion | -87.67% |
| Share Issuances | ₩23.02 Billion | +87.71% |
| Other Changes | ₩26.61 Billion | +101.4% |
| Total Change | ₩- | 35.45% |
Book Value vs Market Value Analysis
This analysis compares Bridge Biotherapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩-401.11 | ₩846.00 | x |
| 2017-12-31 | ₩-1880.58 | ₩846.00 | x |
| 2018-12-31 | ₩-7425.72 | ₩846.00 | x |
| 2019-12-31 | ₩4016.96 | ₩846.00 | x |
| 2020-12-31 | ₩3087.82 | ₩846.00 | x |
| 2021-12-31 | ₩2184.32 | ₩846.00 | x |
| 2022-12-31 | ₩2606.75 | ₩846.00 | x |
| 2023-12-31 | ₩601.55 | ₩846.00 | x |
| 2024-12-31 | ₩520.63 | ₩846.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bridge Biotherapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -907030.66%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.28x
- Recent ROE (-75.27%) is below the historical average (-51.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-1.97 Billion |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-8.69 Billion |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-36.13 Billion |
| 2019 | 1.77% | 2.27% | 0.73x | 1.06x | ₩-6.18 Billion |
| 2020 | -32.47% | -303.35% | 0.10x | 1.07x | ₩-25.16 Billion |
| 2021 | -61.05% | -1365.70% | 0.04x | 1.08x | ₩-30.58 Billion |
| 2022 | -80.40% | -1379.08% | 0.05x | 1.18x | ₩-46.89 Billion |
| 2023 | -218.40% | -42320.90% | 0.00x | 1.77x | ₩-44.26 Billion |
| 2024 | -75.27% | -907030.66% | 0.00x | 1.28x | ₩-22.38 Billion |
Industry Comparison
This section compares Bridge Biotherapeutics Inc's net assets metrics with peer companies in the Capital Markets industry.
Industry Context
- Industry: Capital Markets
- Average net assets among peers: $574,142,101,149
- Average return on equity (ROE) among peers: 0.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bridge Biotherapeutics Inc (288330) | ₩48.42 Billion | 0.00% | 0.15x | $22.91 Million |
| Eugene Inv&Sec (001200) | $495.10 Billion | 0.00% | 6.49x | $202.34 Million |
| Bookook Sec (001270) | $383.10 Billion | 1.54% | 0.69x | $176.21 Million |
| Bookook Securities Co Ltd (001275) | $479.32 Billion | 7.80% | 1.90x | $84.47 Million |
| Sangsangin Investment & Securities Co Ltd (001290) | $150.09 Billion | -2.87% | 2.73x | $28.17 Million |
| Shinyoung Securities Co. Ltd. (001720) | $1.83 Trillion | 5.93% | 4.66x | $417.22 Million |
| Hanyang Sec (001750) | $294.71 Billion | 7.52% | 5.18x | $114.52 Million |
| Hanyang Securities Co Ltd (001755) | $269.85 Billion | 1.72% | 5.84x | $114.52 Million |
| Yuhwa Sec (003460) | $457.55 Billion | 1.67% | 0.38x | $52.28 Million |
| Yuhwa Securities Co Ltd (003465) | $459.41 Billion | 1.72% | 0.38x | $49.53 Million |
| Yuanta Sec Kor (003470) | $919.59 Billion | -18.47% | 6.77x | $301.53 Million |